Exhibit 10.1


 


LICENSE AGREEMENT


This License Agreement (the “Agreement”), effective as
of October 23, 2006 (the “Effective Date”), is entered into by and between
Vical, Inc., a Delaware corporation having offices at 863A Mitten Road,
Burlingame, California 94010 (“Valentis”) and Vical Incorporated, a Delaware
corporation having offices at 10309 Pacific Center Court (“Vical”).  All references to Valentis and Vical in this
Agreement shall include their Affiliates (as defined below).


BACKGROUND


A.            Valentis
is the owner or exclusive licensee of certain Patent Rights and Know-How (as
such terms are defined below), and Vical wishes to acquire a license under the
Patent Rights and Know-How; and


B.            Valentis
is willing to grant Vical such a license, on the terms and conditions set forth
below.


NOW, THEREFORE, in consideration of the promises and
the mutual covenants hereinafter recited, the parties agree as follows:


ARTICLE 1.



DEFINITIONS


In this Agreement, the following terms shall have the
meanings set forth in this Article.


1.1           “Affiliate”
means any company, corporation, division or other entity which is directly or
indirectly controlling, controlled by or under common control with a party
hereto.  For the purpose of this
Agreement, with respect to any company, corporation, division or other entity, “control”
shall mean the direct or indirect ownership of at least fifty percent (50%) of
the outstanding shares or other voting rights of the subject company,
corporation or other entity to elect directors.


1.2            “Confidential
Information” means (a) any proprietary or confidential information
or material in tangible form disclosed hereunder that is marked as “Confidential”
at the time it is delivered to the receiving party, or (b) proprietary or
confidential information disclosed orally hereunder which is identified as
confidential or proprietary when disclosed and such disclosure of confidential
information is confirmed in writing within thirty (30) days by the disclosing
party.


1.3           “Know-How”
means unpatented and/or unpatentable technical information, including ideas,
concepts, inventions, discoveries, data, designs, formulas, specifications,
procedures for experiments and tests and other protocols, results of
experimentation and testing, fermentation and purification techniques, and
assay protocols owned by Valentis as of the Effective Date and Vical after the
Effective Date which may be necessary for the practice of the Valentis Patent
Rights solely as contemplated hereunder. 
Know-How shall not include the Valentis Patent Rights.  All Know-How shall be Confidential
Information of Valentis.









 



1.4            “Vical Products”
means any product or material resulting from Vical’s use of the Licensed
Technology.


1.5           “Licensed Technology”
means the Patent Rights and the Know-How.


1.6           “Patent Rights”
means the patent applications and patents expressly listed in Exhibit A (“Patents”).


1.7            “Third Party”
means any person or entity other than Vical or Valentis.


ARTICLE 2.



LICENSE


2.1           Grant to Vical.  Subject to the terms and conditions of this
Agreement, Valentis hereby grants to Vical for the sum of one hundred eighty
five thousand dollars ($185,000.00) payable in good US funds upon the Effective
Date, a non-exclusive, worldwide, royalty-free, fully paid up license under the
Licensed Technology, without the right to grant sublicenses except to either
(i) a contract manufacturing organization (CMO) for the direct manufacture of
Vical Products or (ii) in connection with a written bona-fide research,
development and collaboration agreement with a Third Party, to:


(a)           make, have made, use
(by a contract manufacturing organization solely for the direct manufacturing
of Vical Products), export and import Vical Products;


2.2           No Implied Rights.  Only the licenses granted pursuant to the
express terms of this Agreement shall be of any legal force or effect.  No other license rights shall be granted or
created by implication, estoppel or otherwise. 
For the avoidance of doubt, by example only and without expanding or
narrowing the license grants of Sections 2.1, the grants of rights made
pursuant to Sections 2.1 do not include, and expressly exclude, any right or
license (a) to engage in any activities on behalf of or in collaboration with
any Third Party (other than, in the case of Vical, as applicable), or (b) to
release or waive any claim of infringement under any patent or patent
application owned or controlled by Valentis or its Affiliates, including,
without limitation, the Patent Rights.


2.3           Ownership; Enforcement;
No Challenge.


(a)           Valentis owns the Licensed
Technology, including all embodiments of the Patent Rights or the Know-How, and
may freely use and commercialize such Licensed Technology itself or with Third
Parties.  Valentis retains the right, at
its sole discretion, to enforce, maintain and otherwise protect the Licensed
Technology.  Vical shall give Valentis
notice of any infringement by a Third Party of any patent or patent application
owned or controlled by Valentis or misappropriation of the Know-How which comes
to Vical’s knowledge during the term of this Agreement.  Vical will cooperate on a commercially
reasonable basis with Valentis with respect to any actions Valentis may choose
to take pursuant to this Section 2.4, and Valentis will reimburse Vical for its
reasonable costs in this regard.



 2
 






 



(b)           Except as required
under applicable law, Vical shall not participate, directly or indirectly, in
any opposition or challenge to the validity or enforceability of any Patent in
any forum and Vical shall not assist any Third Party in any such participation.  Any breach by Vical of this Section 2.5(b)
shall constitute a material breach of this Agreement and any licenses or rights
granted hereunder may, at Valentis’ option, be terminable.


2.4           Reports, Records and
Audits.


(a)           Vical shall maintain
records fully and properly reflecting those activities to be reported to
Valentis pursuant to Section 2.6(a) (the “Records”) in sufficient detail and in
good scientific manner appropriate for patent, regulatory and manufacturing
purposes for at least three (3) years after the date of delivery of the report
containing such information.  Upon the
written request of Valentis and not more than once in each calendar year, Vical
shall permit an independent third party, selected by Valentis and reasonably
acceptable to Vical, at Valentis’ expense, to have access during normal
business hours to such of the Records of Vical as may be reasonably necessary
to verify compliance with the terms of this Agreement, as well as the accuracy
of the reports hereunder.  Vical shall certify
any statements by Vical personnel as to their accuracy and correctness.


ARTICLE 3.



IMPROVEMENTS


Valentis shall be free to research, develop and patent
any improvements to the Licensed Technology and, except as expressly set forth
herein, no rights shall be or are to be construed as granted under this
Agreement to Vical to any patents or patent applications arising from such
activities.


ARTICLE 4.



REPORTS AND RECORDS


4.1           Reports.  Vical shall make a written report to Valentis
within thirty (30) days after each anniversary of the Effective Date describing
Vical’ activities under the rights granted to Vical pursuant to Section
2.1.  Each such report shall also contain
a written certification that Vical is in material compliance with all relevant
terms and conditions of this Agreement. 
Valentis shall treat all such reports as Confidential Information of
Vical.


ARTICLE 5.



CONFIDENTIALITY


5.1           Confidential Information.  Except as expressly provided herein, the
parties agree that, for the term of this Agreement and for five (5) years
thereafter, the receiving party shall keep confidential and shall not publish
or otherwise disclose, and shall not use for any purpose except for the
purposes contemplated by this Agreement, any Confidential Information 



 3
 






 



furnished to such receiving party by a
disclosing party hereto, except to the extent that it can be established by the
receiving party by written proof that such Confidential Information:


(a)           was already known to
the receiving party, other than under an obligation of confidentiality to the
disclosing party, at the time of disclosure;


(b)           was generally
available to the public or otherwise part of the public domain at the time of
its disclosure to the receiving party;


(c)           became generally
available to the public or otherwise part of the public domain after its
disclosure other than through any act or omission of the receiving party in
breach of this Agreement; or


(d)           was subsequently
disclosed to the receiving party by a person or entity with no obligation to
the disclosing party with respect to such information.


5.2           Permitted Use and
Disclosures.  Each party
hereto may use or disclose information disclosed to it by the other party to
the extent such use or disclosure is reasonably necessary for the purposes
contemplated by this Agreement, and in such case pursuant to a confidentiality
agreement no less restrictive than the terms set forth in this Article 6, or in
complying with applicable law or government regulations; provided, however, that if a party is required to make any such
disclosure of the other party’s Confidential Information, other than pursuant
to such a confidentiality agreement, it will give reasonable advance notice to
such other party of such disclosure.


5.3           Confidential Terms.  Except as expressly provided herein, each
party agrees that the terms of this Agreement and the transaction and
relationship with Valentis constitute Confidential Information and are not to
be disclosed to any Third Party without the consent of the other party; provided that disclosures may be made as required by
securities or other applicable laws, or to a party’s accountants, attorneys and
other professional advisors provided,
however, that the party required to make any such disclosure will
give reasonable advance notice to such other party of such disclosure.


5.4           Existence of Agreement.  The parties hereby agree that the
consummation of this Agreement, but not any of the terms hereof, except as
otherwise permitted pursuant to Section 5.3, shall be deemed to be in the
public domain and may be announced or otherwise referred to by a party as
deemed appropriate.


ARTICLE 6.



REPRESENTATIONS AND WARRANTIES


6.1           Representations and
Warranties.


(a)           Valentis represents
and warrants that:  (i) it is the sole
and exclusive owner or exclusive licensee of all right, title and interest in
the Licensed Technology; (ii) it has the legal right, authority and power to
enter into this Agreement, and to grant the licenses granted herein; (iii) this
Agreement shall constitute a valid and binding obligation of 



 4
 






 



Valentis enforceable in accordance with its
terms; and (iv) the performance of its obligations under this Agreement by
Valentis shall not result in a breach of any agreement, contract or other
arrangement to which it is a party.


(b)           Vical represents and
warrants that: (i) it has the legal right, authority and power to enter into
this Agreement; (ii) this Agreement shall constitute a valid and binding
obligation of Vical enforceable in accordance with its terms; and (iii) the
performance of its obligations under this Agreement by Vical shall not result
in a breach of any agreement, contract or other arrangement to which it is a
party.


6.2           Disclaimer.  Nothing in this Agreement is or shall be
construed as:


(a)           A warranty or
representation by Valentis as to the validity or scope of any claim or patent
within the Patent Rights;


(b)           A warranty or
representation by Valentis that anything made, used, sold, or otherwise
disposed of under any license granted in this Agreement is or will be free from
infringement of any patent rights or other intellectual property right of any
Third Party;


(c)           An obligation to
bring or prosecute actions or suits against Third Parties for infringement of
any of the Patent Rights; or


(d)           Granting by
implication, estoppel, or otherwise any licenses or rights under patents or
other rights of Valentis or Third Parties, regardless of whether such patents
or other rights are dominant or subordinate to any patent within the Patent
Rights.


6.3           No Warranties.  EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH
IN SECTION 6.1, NEITHER PARTY GRANTS ANY WARRANTY, EXPRESS OR IMPLIED, EITHER
IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY
SPECIFICALLY DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTY OF TITLE,
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF THE
INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY.


ARTICLE 7.



PATENT PROVISIONS AND INDEMNITY


Valentis shall use commercially reasonable
efforts to give notice to Vical of Valentis’ intent to cease prosecution and/or
maintenance of Patent Rights and, in such case, may offer once to Vical to
permit Vical, and Vical shall promptly accept in writing in Vical’s sole
discretion, to continue prosecution or maintenance at its own expense.  If Vical elects to continue prosecution or
maintenance or file based on Company’s election not to file, Vical shall do so
at its sole expense.  Upon Vical’s
election to continue prosecution or maintenance of the Patent Rights, Valentis
shall cooperate execute such documents and perform such acts at Valentis’
expense as may be reasonably necessary for Vical to perform such prosecution or
maintenance or filing.



 5
 






 



Vical agrees to indemnify, defend and hold Valentis
and its directors, officers, shareholders, employees, contractors and agents
harmless from and against any and all liabilities, claims, demands, expenses
(including, without limitation, attorneys and professional fees and other costs
of litigation), losses or causes of action (each, whether by a Third Party,
Vical, a “Liability”) arising out of (i) the possession, manufacture, use, sale
or other disposition of Vical Products, whether based on breach of warranty,
negligence, product liability or otherwise; (ii) the use by Vical of the
Licensed Technology; (iii) any breach of a warranty, representation or covenant
granted to Valentis hereunder; or (iv) the exercise of any right granted to
Vical, pursuant to this Agreement.


ARTICLE 8.



TERM AND TERMINATION


8.1           Term.  The term of this Agreement will commence on
the Effective Date and remain in full force and effect until the expiration of
the last of the Patents, unless earlier terminated in accordance with this
Article 8.


8.2           Termination for Cause.


(a)           Either party may
terminate this Agreement in the event the other party has materially breached
or defaulted in the performance of any of its obligations hereunder, and such
default has continued for thirty (30) days after written notice thereof was
provided to the breaching party by the non-breaching party.  Any termination shall become effective at the
end of such thirty (30) day period unless the breaching party has cured any
such breach or default prior to the expiration of such period.


8.3           Effect of Termination.


(a)           Accrued Rights and Obligations.  Termination of this Agreement for any reason
shall not release any party hereto from any liability which, at the time of
such termination, has already accrued to the other party or which is
attributable to a period prior to such termination nor preclude either party
from pursuing any rights and remedies it may have hereunder or at law or in
equity with respect to any breach of this Agreement.  It is understood and agreed that monetary
damages may not be a sufficient remedy for any breach of this Agreement and
that the nonbreaching party may be entitled to injunctive relief as a remedy
for any such breach. Such remedy shall not be deemed to be the exclusive remedy
for any such breach of this Agreement, but shall be in addition to all other
remedies available at law or in equity.


(b)           Return of Confidential Information.  Upon any termination of this Agreement, Vical
and Valentis shall promptly return to the other party all Confidential
Information, including without limitation, any know-how received from the other
party (except Valentis may retain copies of any reports or records furnished
pursuant to Articles 2 and 4).


(c)           Licenses. 
Except as expressly provided in this Article 8, all licenses granted
hereunder shall terminate upon the termination of this Agreement.



 6
 






 



8.4           Survival.  Sections 2.6, 5, 6.3, 8.3 and 8.4, Articles
1, 5, 7, and 9 of this Agreement shall survive the expiration or termination of
this Agreement for any reason.


ARTICLE 9.


MISCELLANEOUS PROVISIONS


9.1           Governing Laws.  This Agreement and any dispute, including
without limitation any arbitration, arising from the performance or breach
hereof shall be governed by and construed and enforced in accordance with the
laws of the state of California, without reference to conflicts of laws
principles.


9.2           Assignment.  Neither party may transfer or assign this
Agreement, directly or indirectly, or any of its rights hereunder without the
prior written consent, which shall not be unreasonably withheld, of the other
party, other than (a) to one or more Affiliates, or (b) to a successor in
connection with the transfer or sale of all or substantially all of its
business relating to the subject matter of this Agreement.  Any attempted transfer or assignment in
violation of this Section 9.2 shall be void; provided, (a) this Agreement shall terminate immediately in
the event of a change of control or assignment by Vical to an entity or person
who is the subject matter of a letter sufficient to provide actual notice of
infringement under the applicable statues, any litigation (or re-examination,
interference, opposition or equivalent proceeding) relating to the subject
matter of this Agreement, and/or engaged in active licensing discussions with
Valentis with respect to the Licensed Technology, and (b) that in the event of
a permitted acquisition of all or substantially all of the a party’s assets
relating to the subject matter of this Agreement, the original party’s (or its
successor’s) obligations hereunder shall continue.  This Agreement shall be binding upon and
inure to the benefit of the parties and their permitted successors and assigns.


9.3           Waiver.  No waiver of any rights shall be effective
unless consented to in writing by the party to be charged and the waiver of any
breach or default shall not constitute a waiver of any other right hereunder or
any subsequent breach or default.


9.4           Severability.  In the event that any provisions of this
Agreement are determined to be invalid or unenforceable by a court of competent
jurisdiction, the remainder of the Agreement shall remain in full force and
effect without said provision.


9.5           Notices.  All notices, requests and other
communications hereunder shall be in writing and shall be delivered or sent in
each case to the respective address specified below, or such other address as
may be specified in writing to the other party hereto, and shall be effective
on receipt:


VALENTIS:


Valentis, Inc.


863A Mitten Road


Burlingame, California 94010


Attn:       Benjamin
F. McGraw, III, Pharm. D.


President and
Chief Executive Officer



 7
 






 



with a copy (which shall not constitute notice) to:


Liner Yankelevitz
Sunshine & Regenstreif LLP


199 Fremont St,
20th Floor


San Francisco, Ca
94105


Attn: Gregory Alan Rutchik, Esq.


VICAL INCORPORATED


10390 Pacific
Center Court


San Diego, CA  92121-4340


Attn:  Steven C. Petersen, Esq.


Executive
Director, Intellectual Property


9.6           Independent Contractors.  Both parties are independent contractors
under this Agreement.  Nothing contained
in this Agreement is intended nor is to be construed so as to constitute
Valentis or Vical as partners or joint venturers with respect to this
Agreement.  Except as expressly provided
herein, neither party shall have any express or implied right or authority to
assume or create any obligations on behalf of or in the name of the other party
or to bind the other party to any other contract, agreement, or undertaking
with any Third Party.


9.7           Compliance with Laws.  In exercising their rights under this
license, the parties shall comply in all material respects with the
requirements of any and all applicable laws, regulations, rules and orders of
any governmental body having jurisdiction over the exercise of rights under
this Agreement.  Vical shall, with
respect to the Patent Rights, abide by all applicable patent marking statutes
and, as advised by its own counsel, mark any Vical Products accordingly.


9.8           Bankruptcy.  All rights and licenses granted under or
pursuant to this Agreement by one party to the other are, for all purposes of
Section 365(n) of Title XI of the United States Code (“Title XI”),
licenses of rights to “intellectual property” as defined in Title XI.  During the term of this Agreement each party
shall create and maintain current copies to the extent practicable of all such
intellectual property.  If a bankruptcy
proceeding is commenced by or against one party under Title XI, the other party
shall be entitled to a copy of any and all such intellectual property and all
embodiments of such intellectual property, and the same, if not in the
possession of such other party, shall be promptly delivered to it (a) upon such
party’s written request following the commencement of such bankruptcy
proceeding, unless the party subject to such bankruptcy proceeding, or its
trustee or receiver, elects within thirty (30) days to continue to perform all
of its obligations under this Agreement, or (b) if not delivered as provided
under clause (a) above, upon such other party’s request following the rejection
of this Agreement by or on behalf of the party subject to such bankruptcy
proceeding.  If a party has taken
possession of all applicable embodiments of the intellectual property of the
other party pursuant to this Section 9.8 and the trustee in bankruptcy of the
other party does not reject this Agreement, the party in possession of such
intellectual property shall return such embodiments upon request.  If a party seeks or involuntarily is placed
under Title XI and the trustee rejects this Agreement as contemplated under 11
U.S.C. 365(n)(1), the other party hereby elects, pursuant to Section 



 8
 






 



365(n) of Title XI, to retain all rights
granted to it under this Agreement to the extent permitted by law.


9.9           Use of Names.  Neither party shall use the name or
trademarks of the other party, except to the extent that a party is permitted
to use the Confidential Information of the other party pursuant to Article 5,
without the prior written consent of such other party.


9.10         Further Actions.  Each party agrees to execute, acknowledge and
deliver such further instruments, and do such other acts, as may be necessary
and appropriate in order to carry out the purposes and intent of this
Agreement.


9.11         Limitation of Liability.  IN NO EVENT WILL EITHER PARTY BE LIABLE FOR
ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES ARISING IN ANY WAY
OUT OF THIS AGREEMENT, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY.  THIS LIMITATION WILL APPLY EVEN IF THE OTHER
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE AND NOTWITHSTANDING
ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED WARRANTY PROVIDED HEREIN.


9.12         Arbitration.


(a)           Solely with respect
to any dispute between the parties to this Agreement (other than any dispute
which arises out of or relates to infringement, validity and/or enforceability
of the Patent Rights) upon ten (10) days written notice, any party involved in the
dispute may initiate arbitration by giving notice to that effect to the other
party or parties involved in the dispute and by filing the notice with the
American Arbitration Association or its successor organization (“AAA”)
in accordance with its Commercial Arbitration Rules.  Such dispute shall then be settled by
arbitration in San Mateo County, in accordance with the Commercial Arbitration
Rules of the AAA or other rules agreed to by the parties involved in the dispute,
by a panel of one neutral arbitrator, who shall be selected by the parties
involved in the dispute using the procedures for arbitrator selection of the
AAA.


(b)           The parties
acknowledge that this Agreement evidences a transaction involving interstate
commerce. Insofar as it applies, the United States Arbitration Act shall govern
the interpretation of, enforcement of, and proceedings pursuant to the
arbitration clause in this Agreement. 
Except insofar as the United States Arbitration Act applies to such
matters, the agreement to arbitrate set forth in this Section 9.12 shall be
construed, and the legal relations among the parties shall be determined in
accordance with, the substantive laws of the State of California.


(c)           The arbitrator shall
render its decision and award, including a statement of reasons upon which such
award is based, within thirty (30) days after the arbitration hearing.  The decision shall be in writing and shall be
binding upon the parties involved in the dispute, final and non-appealable.
Judgment upon the award rendered by the panel may be entered in any court
having jurisdiction thereof in accordance with Section 9.13(a).



 9
 






 



(d)           Except as provided
under the United States Arbitration Act and with respect to the infringement,
validity and/or enforceability of the Patent Rights, no action at law or in
equity based upon any dispute that is subject to arbitration under this Section
9.12 shall be instituted.


(e)           All expenses of any
arbitration pursuant to this Section 9.12, including fees and expenses of the
parties’ attorneys, fees and expenses of the arbitrators, and fees and expenses
of any witness or the cost of any proof produced at the request of the
arbitrators, shall be paid by the non-prevailing party.


9.13         Venue; Jurisdiction.


(a)           Any action or
proceeding brought by either party seeking to enforce any provision of, or
based on any right arising out of, this Agreement may be brought against any of
the parties in the courts of the State of California, county of San Mateo.  Each party hereby irrevocably submits to the
jurisdiction of the state courts of the State of California and the country of
San Mateo and to the jurisdiction of any United States District Court in the
State of California, county of San Mateo, for the purpose of any suit, action,
or other proceeding arising out of or based upon this Agreement or the subject
matter hereof brought by any party or its successors or assigns.


(b)           Process in any
action or proceeding seeking to enforce any provision of, or based on any right
arising out of, this Agreement may be served on any party by registered mail at
the address to which notices are to be given pursuant to Section 9.5.  Nothing herein shall affect the right of a
party to serve process in any other manner permitted by applicable law.  Each party further agrees that final judgment
against it in any such action or proceeding arising out of or relating to this
Agreement shall be conclusive and may be enforced in any other jurisdiction
within or outside the United States of America by suit on the judgment, a certified
or exemplified copy of which shall be conclusive evidence of the fact and of
the amount of its liability.


(c)           Each party agrees
that it shall not, and that it shall instruct those in its control not to, take
any action to frustrate or prevent the enforcement of any writ, decree, final
judgment, award (arbitral or otherwise) or order entered against it with
respect to this Agreement or the Patent Rights and shall agree to be bound
thereby as if issued or executed by a competent judicial tribunal having personal
jurisdiction situated in its country of residence or domicile.


9.14         Entire Agreement;
Amendment.  This Agreement
constitutes the entire and exclusive Agreement between the parties with respect
to the subject matter hereof and supersedes and cancels all previous
discussions, agreements, commitments and writings in respect thereof.  No amendment or addition to this Agreement
shall be effective unless reduced to writing and executed by the authorized
representatives of the parties.


9.15         Counterparts.  This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.



 10
 






 



IN WITNESS WHEREOF, Valentis and Vical have executed
this Agreement in duplicate originals by duly authorized officers.


	
  VALENTIS , INC.

  	
  VICAL INCORPORATED 

  
	
   

  	
   

  
	
   

  	
   

  
	
  By: 

  	
  /s/ Benjamin F. McGraw, III

  	
   

  	
  By: 

  	
  /s/ Jill M. Church

  	
   

  
	
   

  	
  Name: 
  Benjamin F. McGraw, III

  	
   

  	
  Name: Jill M. Church

  
	
   

  	
  Title: 
  President and Chief Executive 

  Officer

  	
   

  	
  Title: Vice President and Chief Financial 

  Officer

  
						



 



 11














 


SCHEDULE 1.9


PATENT RIGHTS


	
  Family

  	
   

  	
  Title

  	
   

  	
  Number

  	
   

  	
  Filed/Priority Date

  
	
  1

  	
   

  	
  Methods for Purifying Nucleic Acids (Tangential Flow Ultrafiltration/Diafiltration [UF/DF] for plasmid
  purification)

  	
   

  	
  US6,011,148 WO98/05673
  EP0923592B1 AU717136B2 CA2261150C JP3492702B2

  	
   

  	
  filed 1996-08-01

  
	
  2

  	
   

  	
  Methods for Purifying Nucleic Acids (Purification protocol including static mixing for lysis, TMAE anion
  exchange chromatography and UF/DF for plasmid purification)

  	
   

  	
  WO00/05358 US09/121,798 (US
  Pub. No. 2002/0198372A1) EP1098966A1 AU48638/99A1 CA2338397AA JP2002-521029,A
  (unexamined publication no.)

  	
   

  	
  PCT filed 1999-07-07, claiming priority to
  1998-07-23

  
	
  3

  	
   

  	
  Process and Equipment for Plasmid Purification  (TMAE anion exchange and/or
  hydrophobic interaction chromatography (HIC) for plasmid purification)

  	
   

  	
  US7,026,468 US 11/327,987 (US
  Pub. No. 2006/0106208A1)

  	
   

  	
  filed 1997-07-03, claiming priority to 1996-07-19
  provisional.

  
	
  4

  	
   

  	
  Apparatus and Method for Preparative Scale
  Purification of Nucleic Acids  (flotation of alkaline precipitate for large scale plasmid
  purification)

  	
   

  	
  WO04/024283 US10/527,618 (US
  Pub. No. 2006-0166331A1) EP1554398A2 CA2498518AA AU3267175AA JP2005-538717,A
  (unexamined publication no.)

  	
   

  	
  filed 2003-09-12 as PCT app., claiming priority to
  2002-09-13 (US Provisional)